Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Total Liabilities
Everything the company owes to creditors and other parties.
Evommune, Inc.NYSE: EVMN
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 91.6% from a year ago
Total liabilities stood at $17.9M at the end of Q1 FY2026, down 91.6% from a year earlier and down 7.6% from the prior quarter.
Context
- Total liabilities amounted to 5.6% of total assets at the end of Q1 FY2026, down 376.9 pp from a year earlier.
- Total liabilities increased in 1 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -91.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 19.38M USD
- Year-over-year change
- -91.2%
- 2-year CAGR
- -65.2%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.38M | -91.2% |
| FY2024 | 2024-12-31 | 220.29M | +37.7% |
| FY2023 | 2023-12-31 | 159.96M | — |
Total Liabilities vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 total liabilities of $17.9M is the 9th highest of the 10 companies compared; the peer median is $86.14M.
- Its year-over-year change of -91.6% is the lowest of 10, against a peer median of -2.5%.
- Total liabilities amounts to 5.6% of total assets for EVMN, versus a peer median of 55.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
FTREFortrea Holdings Inc. | Jun 2026 | $2.19B | -2.5% | +31.6% | 80.7% |
| Jun 2026 | $1.22B | +914.7% | +48.7% | 55.7% | |
| Sep 2026 | $918.16M | +1089.2% | -20.6% | 78.0% | |
| Mar 2026 | $397.06M | +19.0% | +2.3% | 302.1% | |
| Mar 2026 | $86.14M | +8.7% | -2.7% | 66.6% | |
| Mar 2026 | $57.75M | -10.0% | -11.7% | 20.0% | |
| Mar 2026 | $31M | -5.1% | -24.8% | 10.6% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $18.11M | -19.4% | -57.5% | 17.1% |
EVMNEvommune, Inc. | Mar 2026 | $17.9M | -91.6% | — | 5.6% |
CLYMClimb Bio, Inc. | Mar 2026 | $4.29M | -41.7% | +5.0% | 2.8% |
| Peer median (excluding EVMN) | $86.14M | -2.5% | -2.7% | 55.7% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.